BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company’s transthyretin amyloid cardiomyopathy ...

An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ...

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...

BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA ...

BridgeBio PharmaBBIO said Sunday its heart-disease drug, Attruby, cut the risk of death almost in half in an exploratory study that one cardiologist says could be a game-changer for the disease.

BridgeBio Pharma recently filed a New Drug Application with the FDA for encaleret in autosomal dominant hypocalcemia type 1, following Phase 3 CALIBRATE results showing rapid, durable improvements in ...

A BridgeBio Pharma drug developed for an increasingly prevalent cardiovascular condition has won FDA approval, marking a comeback for a company and a molecule with a turbulent history. But BridgeBio’s ...

The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...

Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.

BridgeBio Pharma’s stock jumped more than 6% on Thursday after the drugmaker announced promising sales results for its FDA-approved heart drug as part of its latest quarterly earnings release. The ...

1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval, indicating strong initial market uptake. Attruby™ is the first and only near-complete ...

In other recent news, BridgeBio Pharma’s third-quarter earnings have drawn significant attention from various analyst firms. The company reported U.S. sales of its drug Attruby at $108.1 million, ...